Zynerba Pharmaceuticals Total Liabilities

Zynerba Pharmaceuticals (ZYNE) currently reports a total liabilities of $11M as of June 2023. That compares with $9.8M in the prior-year period — up 17.3% year over year. Use the charts on this page to explore Zynerba Pharmaceuticals's total liabilities history and peer comparisons.

Zynerba Pharmaceuticals's total liabilities increased from $9.8M to $11M — a 17.3% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zynerba Pharmaceuticals reported $11M in total liabilities as of June 2023. That compares with $9.8M in the prior-year period — up 17.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zynerba Pharmaceuticals, and consider following ZYNE for alerts when major investors trade the stock.

Zynerba Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZYNE with unrelated industries.